BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11794699)

  • 1. Distinctive multidrug sensitivity and outcome of acute erythroblastic and megakaryoblastic leukemia in children with Down syndrome.
    Yamada S; Hongo T; Okada S; Watanabe C; Fujii Y; Hori H; Yazaki M; Hanada R; Horikoshi Y
    Int J Hematol; 2001 Dec; 74(4):428-36. PubMed ID: 11794699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythroblastic and/or megakaryoblastic leukemia in Down syndrome: treatment with low-dose arabinosyl cytosine.
    Tchernia G; Lejeune F; Boccara JF; Denavit MF; Dommergues JP; Bernaudin F
    J Pediatr Hematol Oncol; 1996 Feb; 18(1):59-62. PubMed ID: 8556372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group.
    Kudo K; Kojima S; Tabuchi K; Yabe H; Tawa A; Imaizumi M; Hanada R; Hamamoto K; Kobayashi R; Morimoto A; Nakayama H; Tsuchida M; Horibe K; Kigasawa H; Tsukimoto I;
    J Clin Oncol; 2007 Dec; 25(34):5442-7. PubMed ID: 18048827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia.
    Taub JW; Matherly LH; Stout ML; Buck SA; Gurney JG; Ravindranath Y
    Blood; 1996 Apr; 87(8):3395-403. PubMed ID: 8605357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome.
    Kojima S; Sako M; Kato K; Hosoi G; Sato T; Ohara A; Koike K; Okimoto Y; Nishimura S; Akiyama Y; Yoshikawa T; Ishii E; Okamura J; Yazaki M; Hayashi Y; Eguchi M; Tsukimoto I; Ueda K
    Leukemia; 2000 May; 14(5):786-91. PubMed ID: 10803507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down syndrome, drug metabolism and chromosome 21.
    Taub JW; Ge Y
    Pediatr Blood Cancer; 2005 Jan; 44(1):33-9. PubMed ID: 15390307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome.
    Savaşan S; Buck S; Raimondi SC; Becton DL; Weinstein H; Chang M; Ravindranath Y
    Leuk Lymphoma; 2006 Oct; 47(10):2076-83. PubMed ID: 17071479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.
    Gamis AS; Woods WG; Alonzo TA; Buxton A; Lange B; Barnard DR; Gold S; Smith FO;
    J Clin Oncol; 2003 Sep; 21(18):3415-22. PubMed ID: 12885836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome.
    Hama A; Yagasaki H; Takahashi Y; Nishio N; Muramatsu H; Yoshida N; Tanaka M; Hidaka H; Watanabe N; Yoshimi A; Matsumoto K; Kudo K; Kato K; Horibe K; Kojima S
    Br J Haematol; 2008 Mar; 140(5):552-61. PubMed ID: 18275433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
    Langebrake C; Creutzig U; Reinhardt D
    Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosome 7 abnormalities in acute megakaryoblastic leukemia associated with Down syndrome.
    Kobayashi K; Usami I; Kubota M; Nishio T; Kakazu N
    Cancer Genet Cytogenet; 2005 Apr; 158(2):184-7. PubMed ID: 15796967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treatment of children with acute megakaryoblastic leukemia who have Down syndrome.
    Zipusky A
    J Pediatr Hematol Oncol; 1996 Feb; 18(1):10-2. PubMed ID: 8556363
    [No Abstract]   [Full Text] [Related]  

  • 13. Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and transient myeloproliferative disease in children with and without Down syndrome.
    Boztug H; Schumich A; Pötschger U; Mühlegger N; Kolenova A; Reinhardt K; Dworzak M
    Cytometry B Clin Cytom; 2013; 84(6):370-8. PubMed ID: 23450818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891.
    Lange BJ; Kobrinsky N; Barnard DR; Arthur DC; Buckley JD; Howells WB; Gold S; Sanders J; Neudorf S; Smith FO; Woods WG
    Blood; 1998 Jan; 91(2):608-15. PubMed ID: 9427716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased levels of a chromosome 21-encoded tumour invasion and metastasis factor (TIAM1) mRNA in bone marrow of Down syndrome children during the acute phase of AML(M7).
    Ives JH; Dagna-Bricarelli F; Basso G; Antonarakis SE; Jee R; Cotter F; Nizetić D
    Genes Chromosomes Cancer; 1998 Sep; 23(1):61-6. PubMed ID: 9713998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
    Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
    Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
    Creutzig U; Reinhardt D; Diekamp S; Dworzak M; Stary J; Zimmermann M
    Leukemia; 2005 Aug; 19(8):1355-60. PubMed ID: 15920490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome.
    Al-Ahmari A; Shah N; Sung L; Zipursky A; Hitzler J
    Br J Haematol; 2006 Jun; 133(6):646-8. PubMed ID: 16704441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis.
    Ariffin H; Garcia JC; Daud SS; Ibrahim K; Aizah N; Ong GB; Chong LA; Mohamad Z
    Pediatr Blood Cancer; 2009 Jul; 53(1):108-11. PubMed ID: 19260099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The value of intracellular CD41 antigen detection to the diagnosis of acute megakaryoblastic leukemia].
    Miki J; Koike K; Sawai N; Matsuura H; Kurokawa Y; Sakashita K; Nakazawa T; Ito S; Hidaka E; Koike T; Komiyama A
    Rinsho Ketsueki; 1999 Jul; 40(7):568-73. PubMed ID: 10483140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.